Amplia Therapeutics Ltd. Updates: Focus on Immuno-Oncology Drug Discovery
Melbourne-based biotechnology company, Amplia Therapeutics Ltd., continues to make strides in the health care sector with its focus on immuno-oncology drug discovery. The company, listed on the ASX All Markets stock exchange, specializes in developing innovative treatments for cancer and tumors, serving a global customer base.
As of June 16, 2025, Amplia Therapeutics’ share price closed at 0.076 AUD. This figure reflects a significant fluctuation over the past year, with the stock reaching a 52-week high of 0.18 AUD on September 23, 2024, and a low of 0.049 AUD on May 29, 2025. The company’s market capitalization currently stands at 25,604,878 AUD.
Amplia Therapeutics is dedicated to advancing immuno-oncology therapies, aiming to improve outcomes for patients with various diseases. Their research and development efforts are centered on harnessing the body’s immune system to combat cancer more effectively.
For more information about Amplia Therapeutics Ltd. and their ongoing projects, interested parties can visit their official website at www.ampliatx.com .